Kazia Therapeutics Limited (KZIA) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kazia Therapeutics Limited  (NASDAQ: KZIA)

Kazia Therapeutics Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Kazia Therapeutics Limited in the fourth quarter 2025?
Due to the lack of equity, it was not possible to calculate Kazia Therapeutics Limited's return on equity (ROE) in its fourth quarter 2025

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2024)
IV. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -21 -27 -27 -27 -27
Return On Equity (TTM) - - - - -
KZIA's Total Ranking # # # # #
Equity (TTM) in Millions -8 -5 -5 -8 -7
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to KZIA Management Effectiveness >> KZIA's 5 Years Annual ROE >> Compare KZIA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





KZIA Annual Return On Equity (Jun 30 2025)
2025		 (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022		 (Jun 30 2021)
2021
Total Equity in Millions 0 0 12 19 28
Y / Y Equity Change - - -35.35 % -34.31 % 191.41 %
Net Income in Millions -21 -27 -20 -25 -8
Y / Y Net Income Change - - - - -
Return On Equity - - -169.83 % -132.25 % -29.68 %

Back to KZIA Management Effectiveness >> KZIA's 5 Years Annual ROE >> Compare KZIA ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
KZIA's' Return on Equity at Yahoo Finance
KZIA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for KZIA's Competitors
Subscribers only: Roe for Kazia Therapeutics Limited's Suppliers
Subscribers only: Return On Equity for KZIA's Customers




Companies with similar Return On Equity at Jun 30 2025, within Healthcare Sector ROE
Pavmed Inc   538.00 %
Davita Inc   531.07 %
Rigel Pharmaceuticals Inc  438.89 %
Seres Therapeutics Inc   283.91 %
Capforce Inc   224.17 %
Champions Oncology Inc   191.98 %
Cytomx Therapeutics Inc   158.55 %
Abbvie Inc   140.20 %
Halozyme Therapeutics Inc   136.63 %
Organon and Co   125.00 %
Amgen Inc   97.92 %
3m Company  90.51 %
Eli Lilly And Company  87.91 %
Stablecoin Development Corporation  81.69 %
Earth Science Tech Inc   78.03 %
Abeona Therapeutics Inc   77.68 %
Biomx Inc  70.26 %
Medpace Holdings Inc   67.66 %
Dariohealth Corp   65.89 %
Medinotec Inc   65.57 %
Idexx Laboratories Inc  64.42 %
Exelixis Inc   63.47 %
Adma Biologics Inc   61.78 %
Nrc Health  61.35 %

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.